Table 2.
An overview of different targeting ligand decorated PLGA NPs with their preparation methods, ligands used, payloads, size, and zeta potential.
| NPs type | NP preparation method | Targeting ligand | Loaded Materials | Stabilizer | Cell line/animal model | Average size (nm) |
Zeta potential (mV) |
Reference |
|---|---|---|---|---|---|---|---|---|
| PEG | Top-down strategic PRINT technique | Transferrin | — | — | HeLa, Ramos, H460, SK-OV-3, HepG2, LNCaP | (267 ± 49)–(292 ± 76) | (−35.6 ± 1.3)–(39.9 ± 1.7) | [66] |
|
| ||||||||
| PEG-PCL | Dry-down method | Alexa Fluor 647 (AF647) | — | — | MDA-MB-468, MCF-7 | (26.4 ± 0.7)–(60.9 ± 0.7) | (−5.1)–(−7.3) | [67] |
|
| ||||||||
| PEG-PCL | Solvent evaporation | Angiopep-2 | Paclitaxel | Sodium Cholate | U87 MG, BCECs | <100 | (−3.08 ± 0.94)–(−3.28 ± 0.75) | [68] |
|
| ||||||||
| PLGA | Nanoprecipitation | g7 Peptide | Loperamide, Rhodamine-123 | Poloxamer 188 | Tail vein in rats | 140–180 | −20 | [69] |
|
| ||||||||
| PLGA | Modified solvent extraction/evaporation | Trastuzumab | Paclitaxel | PVA | Caco-2, SK-BR-3 | (293.8 ± 5.7)–(312.3 ± 8.2) | (−35.07 ± 1.68)–(−21.24 ± 2.11) | [70] |
|
| ||||||||
| PLGA | Emulsion-solvent evaporation/extraction | Humanized anti-DC-SIGN (hD1) | FITC-TT peptide, DQ-BSA | PVA | Granulocytes, PBMCs | 202 ± 4, 239 ± 14 | (−28.6 ± 0.4), (−44.9 ± 1.8) | [71] |
|
| ||||||||
| PLGA-PEG | Nanoprecipitation | A10 PSMA aptamer | Cisplatin | — | LNCaP, PC3 | (131 ± 0.5)–(172 ± 3.4) | — | [72] |
|
| ||||||||
| PLGA-PEG | Emulsion-solvent evaporation | Pep TGN | Coumarin-6 | — | bEnd.3 | (104.17 ± 3.45)–(121.46 ± 0.76) | (−24.43 ± 0.22)–(−18.25 ± 0.88) | [73] |
|
| ||||||||
| PLGA-PEG | Solvent-diffusion | cRGD peptide | Doxorubicin | PEMA | MDA-MB-231, B16F10, MCF-7 | (366.6 ± 3.1)–(423.0 ± 16.6) | (−18.9 ± 2.4)–(−51.7 ± 3.1) | [74] |
|
| ||||||||
| PLGA-PEG | Nanoprecipitation | A10 2′-fluoropyrimidine RNA aptamers | Docetaxel | — | LNCaP | (153.3 ± 13.9) | −42 ± 1 | [75] |
|
| ||||||||
| PLGA–PEG | Emulsion-solvent diffusion | Folate binding protein | Docetaxel | PVA | SKOV3 | (120 ± 5)–(216 ± 18) | (−6.27 ± 0.95)–(−12.2 ± 0.6) | [76] |
|
| ||||||||
| PLGA-TPGS | Solvent extraction/evaporation | TPGS | Docetaxel | TPGS | Caco-2, MCF-7 | (219.42 ± 5.24)–(253.51 ± 5.38) | (−21.87 ± 2.11)–(34.1 ± 4.28) | [77] |
|
| ||||||||
| PLGA-TPGS | Solvent extraction/evaporation | Vitamin E TPGS-folate (TPGS-FOL) | Doxorubicin | — | MCF-7, C6 glioma | (324 ± 5)–(359 ± 10) | — | [78] |